CTLA4 and gastric cancer: Immune checkpoint blockade therapy targeting programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has emerged as a promising treatment option for gastric cancer.